Dan represents biotech and pharmaceutical companies in all areas of patent counseling, including lifecycle management, patent portfolio development and restructuring, post-issuance proceedings, investment and transactional intellectual property due diligence and offensive and defensive patent strategy. He is a registered patent lawyer.
Dan has extensive experience in pharmaceutical lifecycle management, both for marketed pharmaceutical products and for products in late-stage clinical development that require additional patent term. Prior to joining Fenwick, Dan was responsible for worldwide prosecution of a second-generation patent family protecting the world’s best-selling prescription pharmaceutical, including coordinating successful defense against 15 European opponents. For a venture-backed company repurposing a drug product that had earlier failed phase 3 clinical trials in a different indication, Dan designed a strategy for newly claiming the drug substance per se, including advice on new in vitro experiments, drafting, filing and prosecution of a new patent family, achieving allowance of Orange Book-listable claims shortly after acquisition of the company for $325 million upfront plus $120 million in contingent value rights.
He goes above and beyond, knows the space of genetic medicine really well, and has a tremendous eye for detail.”
—Chambers USA, Client Quote
2023 Edition
Recognition Recognition Recognition
Recognition Recognition Recognition
2010 – 2022
Named a Life Sciences Star by LMG Life Sciences, ranking him among the preeminent life sciences practitioners in the U.S.
2019 – 2020, 2023
Recognized as an IP Star by Managing Intellectual Property
2024
A leading lawyer for California: Intellectual Property: Patent Prosecution
2015 – 2024
Recommended by The Legal 500 in the categories of Patents: Prosecution (including re-examination and post-grant proceedings) (2020 – 2024) and Patent Portfolio Management and Licensing (2015, 2016 and 2018)
2018 – 2024
Recognized by IAM Patent 1000 for patent prosecution in California, with the publication highlighting his work with overseas transactions and post-grant actions